News & Updates

Patients with Alagille syndrome (AS) may benefit from treatment with odevixibat, with the phase III ASSERT study showing that its use results in rapid, sustained, and highly significant improvements in pruritus, sleep quality, as well as decreases in bile acids (BAs). Odevixibat is also well tolerated.

Use of teduglutide is effective against short bowel syndrome (SBS) in paediatric patients, although some children need a longer duration of treatment to achieve enteral autonomy, according to a Spain study presented at ESPGHAN 2023. Predictive factors of response to treatment have not been identified.

Treatment with dupilumab significantly improves histologic and endoscopic measures of eosinophilic esophagitis (EoE) in young children aged 1–11 years, according to the phase III EoE KIDS trial presented at ESPGHAN 2023.

An elevated proportion of children and adolescents around the world, particularly girls or those with high BMI, experience disordered eating as shown in a meta-analysis of 32 studies from 16 countries.

Adding the probiotic Limosilactobacillus reuteri (L. reuteri) DSM 17938 to antibiotic therapy significantly reduced the incidence of antibiotic-associated diarrhoea (AAD) in children with acute otitis media or acute bacterial sinusitis in the PEARL study presented at ESPGHAN 2023.

Treatment with teduglutide for 48 weeks results in increased intestinal absorption and decreased parenteral nutrition (PN) dependency in children with short bowel syndrome (SBS)-related intestinal failure (IF), as shown in a study.

Children and adolescents with better cardiorespiratory endurance appear to have a reduced risk of inflammatory bowel disease (IBD), as shown in a study.

Coeliac disease (CeD) appears to be common in patients with cryptogenic cirrhosis or cryptogenic hypertransaminasaemia, suggests a study, noting that these individuals must be considered high-risk groups for CeD.